✦ LIBER ✦

Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial

✍ Scribed by Azim, Hatem A.; Rothé, Francoise; Aura, Claudia Monica; Bavington, Malcolm; Maetens, Marion; Rouas, Ghizlaine; Gebhart, Geraldine; Gamez, Cristina; Eidtmann, Holger; Baselga, José; Piccart-Gebhart, Martine; Ellis, Catherine; Vuylsteke, Peter; Cure, Hervé; Domont, Julien; Ferro, Antonella; Toral-Peña, Juan Carlos; de Azambuja, Evandro; Sotiriou, Christos; Di Cosimo, Serena; Ignatiadis, Michail

Book ID: 122655032
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 468 KB
Volume: 22
Category: Article
ISSN: 0960-9776
DOI: 10.1016/j.breast.2013.08.014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

191 DETECT III – a Multicenter, Randomiz

191 DETECT III – a Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells

✍ C.A. Melcher; W. Janni; B. Rack; V. Muller; A. Schneeweiss; K. Pantel; E.F. Solo 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 78 KB

Phase 2 trial of primary systemic therap

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099

✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views